Does Medicare Pay for GLP-1 Medications? (2026)
What Medicare pays for, what it asks of you first, what it costs when the answer is yes, and where to go when it is no.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Where Each Medication Stands[8]
| Medication | What Medicare does |
|---|---|
| Wegovy (semaglutide) | Medicare Part D excludes drugs prescribed for weight loss under the statutory exclusion at SSA 1860D-2(e)(2)(A). Per CMS HPMS memo issued March 20, 2024, Wegovy may be covered under Part D when prescribed for the FDA-approved cardiovascular-risk-reduction indication (reducing risk of MACE in adults with established CVD who are obese or overweight, supported by the SELECT trial). Plan-level coverage and PA criteria vary. |
| Ozempic (semaglutide) | Covered under Medicare Part D for type 2 diabetes diagnosis. |
| Zepbound (tirzepatide) | Not covered under Medicare Part D for weight loss (statutory exclusion). Zepbound has a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity; Part D coverage for the OSA indication is plan-dependent. |
| Mounjaro (tirzepatide) | Covered under Medicare Part D for type 2 diabetes diagnosis. |
| Copay when it is covered | $30-$100 / month |
After a Denial from Medicare
A refusal on Wegovy or Zepbound is not the end of the road. Licensed 503A pharmacies[7] dispense compounded semaglutide and tirzepatide at $149-$299 a month, well under what the brand costs. Two other things are worth knowing. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[5], and a good number of plan administrators will accept a compounded one on a Letter of Medical Necessity. The services listed below ship to all 50 states and usually write inside the week.
Why Medicare is different: statute settles this one, not plan policy. Part D cannot pay for what the law calls “agents when used for anorexia, weight loss, or weight gain”, a bar written into the Social Security Act at § 1860D-2(e)(2)(A). So an obesity indication gets nowhere with Wegovy or Zepbound, even on a plan whose formulary already lists them for diabetes or cardiovascular use[3].
Lodge the formal appeal with Medicare first. Ask your prescriber for a Letter of Medical Necessity that documents your BMI, any comorbidities, and the weight-loss attempts that did not work. Appeals carrying one overturn a real share of denials.
Cash-pay GLP-1 services if Medicare says no
Cash-pay compounded semaglutide and tirzepatide are not hard to find, and after a denial the monthly cost often lands under what a covered copay would have been. Our highest-ranked picks come first, then the longer list.
Our picks
Compare the top providers at a glance
Every row carries a logo, our editorial rating, price, the medications prescribed, and where the seller ships. Scan down a column and the list shortens fast.
- ★ Editor's Pick
semaglutide at $99/month, 48% under the register median
From /mo$99Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
semaglutide at $99/month, 48% under the register median
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide - Nationwide Coverage
tirzepatide at $169/month, 37% under the register median
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide moving between compounded and brand without changing seller
From /mo$129Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatidesemaglutide at $99/month, 48% under the register median
From /mo$99Coverage49 statesMedicationsSemaglutideTirzepatide
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick semaglutide at $99/month, 48% under the register median | $99 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
Best Budget semaglutide at $99/month, 48% under the register median | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
Nationwide Coverage tirzepatide at $169/month, 37% under the register median | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
 moving between compounded and brand without changing seller | $129 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
 semaglutide at $99/month, 48% under the register median | $99 | SemaglutideTirzepatide | 49 states | Visit → |
The longer list of compounded options
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Kairos Aesthetic and Longevity Medicine
Best for: a published state list — 1 of 50 — when most of the register publishes none
Editorial score · methodology
Get StartedRead full Kairos Aesthetic and Longevity Medicine review →Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Trimrose
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Off-label use · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Medicare coverage changes
We will email you if Medicare changes its GLP-1 rules.
Sources & methodology — as of August 2026
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 6.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 7.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 8.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.